1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Primary Biliary Cirrhosis Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Budesonide
1.4.3 FFP-104
1.4.4 GSK-2330672
1.4.5 MBX-8025
1.4.6 NGM-282
1.4.7 Others
1.5 Market by Application
1.5.1 Global Primary Biliary Cirrhosis Drug Market Share by Application: 2021-2026
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Primary Biliary Cirrhosis Drug Market
1.8.1 Global Primary Biliary Cirrhosis Drug Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Primary Biliary Cirrhosis Drug Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Primary Biliary Cirrhosis Drug Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Primary Biliary Cirrhosis Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Primary Biliary Cirrhosis Drug Sales Volume Market Share by Region (2015-2020)
3.2 Global Primary Biliary Cirrhosis Drug Sales Revenue Market Share by Region (2015-2020)
3.3 North America Primary Biliary Cirrhosis Drug Sales Volume
3.3.1 North America Primary Biliary Cirrhosis Drug Sales Volume Growth Rate (2015-2020)
3.3.2 North America Primary Biliary Cirrhosis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Primary Biliary Cirrhosis Drug Sales Volume
3.4.1 East Asia Primary Biliary Cirrhosis Drug Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Primary Biliary Cirrhosis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Primary Biliary Cirrhosis Drug Sales Volume (2015-2020)
3.5.1 Europe Primary Biliary Cirrhosis Drug Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Primary Biliary Cirrhosis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Primary Biliary Cirrhosis Drug Sales Volume (2015-2020)
3.6.1 South Asia Primary Biliary Cirrhosis Drug Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Primary Biliary Cirrhosis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Primary Biliary Cirrhosis Drug Sales Volume (2015-2020)
3.7.1 Southeast Asia Primary Biliary Cirrhosis Drug Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Primary Biliary Cirrhosis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Primary Biliary Cirrhosis Drug Sales Volume (2015-2020)
3.8.1 Middle East Primary Biliary Cirrhosis Drug Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Primary Biliary Cirrhosis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Primary Biliary Cirrhosis Drug Sales Volume (2015-2020)
3.9.1 Africa Primary Biliary Cirrhosis Drug Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Primary Biliary Cirrhosis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Primary Biliary Cirrhosis Drug Sales Volume (2015-2020)
3.10.1 Oceania Primary Biliary Cirrhosis Drug Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Primary Biliary Cirrhosis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Primary Biliary Cirrhosis Drug Sales Volume (2015-2020)
3.11.1 South America Primary Biliary Cirrhosis Drug Sales Volume Growth Rate (2015-2020)
3.11.2 South America Primary Biliary Cirrhosis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Primary Biliary Cirrhosis Drug Sales Volume (2015-2020)
3.12.1 Rest of the World Primary Biliary Cirrhosis Drug Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Primary Biliary Cirrhosis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Primary Biliary Cirrhosis Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Primary Biliary Cirrhosis Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Primary Biliary Cirrhosis Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Primary Biliary Cirrhosis Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Primary Biliary Cirrhosis Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Primary Biliary Cirrhosis Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Primary Biliary Cirrhosis Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Primary Biliary Cirrhosis Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Primary Biliary Cirrhosis Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Primary Biliary Cirrhosis Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Primary Biliary Cirrhosis Drug Sales Volume Market Share by Type (2015-2020)
14.2 Global Primary Biliary Cirrhosis Drug Sales Revenue Market Share by Type (2015-2020)
14.3 Global Primary Biliary Cirrhosis Drug Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Primary Biliary Cirrhosis Drug Consumption Volume by Application (2015-2020)
15.2 Global Primary Biliary Cirrhosis Drug Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Primary Biliary Cirrhosis Drug Business
16.1 AlbireoPharma
16.1.1 AlbireoPharma Company Profile
16.1.2 AlbireoPharma Primary Biliary Cirrhosis Drug Product Specification
16.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 MediGene AG
16.2.1 MediGene AG Company Profile
16.2.2 MediGene AG Primary Biliary Cirrhosis Drug Product Specification
16.2.3 MediGene AG Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Enanta Pharmaceuticals, Inc.
16.3.1 Enanta Pharmaceuticals, Inc. Company Profile
16.3.2 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Specification
16.3.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 CymaBay Therapeutics, Inc.
16.4.1 CymaBay Therapeutics, Inc. Company Profile
16.4.2 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Specification
16.4.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Johnson & Johnson
16.5.1 Johnson & Johnson Company Profile
16.5.2 Johnson & Johnson Primary Biliary Cirrhosis Drug Product Specification
16.5.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Dr. Falk Pharma GmbH
16.6.1 Dr. Falk Pharma GmbH Company Profile
16.6.2 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Specification
16.6.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Virobay Inc.
16.7.1 Virobay Inc. Company Profile
16.7.2 Virobay Inc. Primary Biliary Cirrhosis Drug Product Specification
16.7.3 Virobay Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Intercept Pharmaceuticals, Inc.
16.8.1 Intercept Pharmaceuticals, Inc. Company Profile
16.8.2 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Specification
16.8.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 GlaxoSmithKline Plc
16.9.1 GlaxoSmithKline Plc Company Profile
16.9.2 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Specification
16.9.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 NGM Biopharmaceuticals, Inc.
16.10.1 NGM Biopharmaceuticals, Inc. Company Profile
16.10.2 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Specification
16.10.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Primary Biliary Cirrhosis Drug Manufacturing Cost Analysis
17.1 Primary Biliary Cirrhosis Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Primary Biliary Cirrhosis Drug
17.4 Primary Biliary Cirrhosis Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Primary Biliary Cirrhosis Drug Distributors List
18.3 Primary Biliary Cirrhosis Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Primary Biliary Cirrhosis Drug (2021-2026)
20.2 Global Forecasted Revenue of Primary Biliary Cirrhosis Drug (2021-2026)
20.3 Global Forecasted Price of Primary Biliary Cirrhosis Drug (2015-2026)
20.4 Global Forecasted Production of Primary Biliary Cirrhosis Drug by Region (2021-2026)
20.4.1 North America Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)
20.4.3 Europe Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)
20.4.7 Africa Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)
20.4.9 South America Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Primary Biliary Cirrhosis Drug by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country
21.2 East Asia Market Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country
21.3 Europe Market Forecasted Consumption of Primary Biliary Cirrhosis Drug by Countriy
21.4 South Asia Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country
21.5 Southeast Asia Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country
21.6 Middle East Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country
21.7 Africa Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country
21.8 Oceania Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country
21.9 South America Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country
21.10 Rest of the world Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer